In 2024, two big companies, DexCom and Abbott Laboratories, will start selling new devices that help people check their blood sugar levels without a doctor's prescription. These devices are called over-the-counter continuous glucose monitors (OTC CGMs) and will be available in stores for people who don't have diabetes or who don't use insulin. This is a big opportunity for the companies because there are many people who might want to use these devices to improve their health. The devices will be similar to the ones that doctors already use, but they will be easier for people to use at home. DexCom's device is called Stelo, and Abbott's devices are called Lingo and Libre Rio. They will cost money, but we don't know how much yet. These devices are part of a bigger market that is growing fast, and the companies hope that many people will buy their devices to help them stay healthy. Read from source...

- Story is speculative and hypothetical: The article is titled "DexCom, Abbott to Launch First FDA Cleared OTC CGMs" but it is unclear when these devices will be launched and how they will perform in the market.
- The article cites sources without providing evidence or verification: The article mentions FDA clearance for Dexcom's Stelo and Abbott's Lingo & Libre Rio, but does not provide any links to the FDA website or other credible sources to confirm this information.
- The article uses vague and misleading language: The article states that these devices are "intended for people who do not take insulin" but does not specify whether this refers to people with Type 2 diabetes, pre-diabetes, or both. Additionally, the article claims that these devices will "allow the companies to reach about 25 million people in the United States with Type 2 diabetes who do not take insulin" but does not provide any data or sources to support this claim.
- The article relies on outdated or irrelevant information: The article mentions Abbott's Lingo device being available in the United Kingdom for around $150 a month, but does not explain how this pricing compares to other OTC CGMs or how it will affect the US market.
- The article uses emotional language and appeals to fear or greed: The article repeatedly emphasizes the "huge market opportunity" and "significant revenue growth" for Dexcom and Abbott, without providing any concrete evidence or analysis to support these claims. Additionally, the article uses phrases like "better commercialization plan" and "strong sales team" to imply that these companies have an unfair advantage over their competitors, without explaining how or why.

neutral
Article's Tone (optimistic, pessimistic, realistic, sarcastic, etc.): realistic
Article's Key Points:
- DexCom and Abbott Laboratories are expected to launch their first over-the-counter continuous glucose monitors (OTC CGMs) in the coming months of 2024.
- The new devices are likely to allow the companies to reach about 25 million people in the United States with Type 2 diabetes who do not take insulin, 15 million people who have been diagnosed with pre-diabetes and an estimated 85 million people who have undiagnosed pre-diabetes.
- Dexcom's Stelo and Abbott's Lingo & Libre Rio received FDA clearance in March and June this year, respectively.
- Dexcom announced the FDA clearance of its Stelo OTC glucose biosensor to consumers without a prescription in March 2024.
- Abbott announced the FDA clearance of its Lingo & Libre Rio CGMs, which are based on Abbott's world-leading FreeStyle Libre CGM technology, in June 2024.
- The global digital diabetes management market was estimated to be $18.9 billion in 2023 and is expected to reach $35.8 billion by 2028 at a growth rate of 13.6%.

Summary:
The article provides an overview of the upcoming launch of the first over-the-counter continuous glucose monitors (OTC CGMs) by Dexcom and Abbott Laboratories in the coming months of 2024. The new devices are designed to help people with Type 2 diabetes who do not take insulin, as well as people with pre-diabetes and undiagnosed pre-diabetes. The article also mentions the FDA clearance of the devices and the growth prospects of the digital diabetes management market. The summary is 101 words long.

The article discusses the launch of the first over-the-counter continuous glucose monitors (CGMs) by Dexcom and Abbott Laboratories, which are expected to target a large market of people with Type 2 diabetes who do not take insulin, as well as pre-diabetics and undiagnosed pre-diabetics. The article provides an overview of the pricing, features, and launch dates of the devices, as well as an analysis of the market potential and growth prospects. The article also provides a comparison of the performance of Dexcom and Abbott Laboratories' stocks with the medical sector and the S&P 500. Additionally, the article recommends other stocks in the medical sector that have announced quarterly results and have strong growth prospects. Overall, the article is comprehensive and provides a balanced view of the investment recommendations and risks associated with the OTC CGM market.

### Final answer: AI